Citius Pharmaceuticals Stock Price Prediction

CTXR Stock  USD 1.65  0.01  0.61%   
As of today, the relative strength index (RSI) of Citius Pharmaceuticals' share price is approaching 39 suggesting that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Citius Pharmaceuticals, making its price go up or down.

Momentum 39

 Sell Extended

 
Oversold
 
Overbought
The successful prediction of Citius Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Citius Pharmaceuticals and does not consider all of the tangible or intangible factors available from Citius Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Citius Pharmaceuticals, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Citius Pharmaceuticals' stock price prediction:
EPS Estimate Current Year
1.35
EPS Estimate Next Year
2.985
Wall Street Target Price
39
EPS Estimate Current Quarter
(0.04)
Using Citius Pharmaceuticals hype-based prediction, you can estimate the value of Citius Pharmaceuticals from the perspective of Citius Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Citius Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Citius because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Citius Pharmaceuticals after-hype prediction price

    
  USD 1.58  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Citius Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Citius Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
0.122.397.97
Details
3 Analysts
Consensus
LowTargetHigh
4.254.675.18
Details
Earnings
Estimates (0)
LowProjected EPSHigh
1.301.301.30
Details

Citius Pharmaceuticals After-Hype Price Prediction Density Analysis

As far as predicting the price of Citius Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Citius Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Citius Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
   Next price density   
JavaScript chart by amCharts 3.21.151.371.421.481.531.581.631.681.741.79 Price after next news: 1.58 0.01302340.01302350.01302360.01302370.0130238
       Expected price to next headline  

Citius Pharmaceuticals Estimiated After-Hype Price Volatility

In the context of predicting Citius Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Citius Pharmaceuticals' historical news coverage. Citius Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.08 and 7.16, respectively. We have considered Citius Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
1.65
1.58
After-hype Price
7.16
Upside
Citius Pharmaceuticals is dangerous at this time. Analysis and calculation of next after-hype price of Citius Pharmaceuticals is based on 3 months time horizon.

Citius Pharmaceuticals Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Citius Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Citius Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Citius Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.94 
5.53
  0.07 
  0.08 
6 Events / Month
11 Events / Month
In about 6 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
1.65
1.58
4.24 
7,900  
Notes

Citius Pharmaceuticals Hype Timeline

Citius Pharmaceuticals is currently traded for 1.65. The entity has historical hype elasticity of -0.07, and average elasticity to hype of competition of -0.08. Citius is anticipated to decline in value after the next headline, with the price expected to drop to 1.58. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -4.24%, whereas the daily expected return is currently at -0.94%. The volatility of related hype on Citius Pharmaceuticals is about 6411.59%, with the expected price after the next announcement by competition of 1.57. The company has price-to-book (P/B) ratio of 0.22. Some equities with similar Price to Book (P/B) outperform the market in the long run. Citius Pharmaceuticals recorded a loss per share of 5.82. The entity last dividend was issued on the 9th of June 2017. The firm had 1:25 split on the 26th of November 2024. Given the investment horizon of 90 days the next anticipated press release will be in about 6 days.
Check out Citius Pharmaceuticals Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.
JavaScript chart by amCharts 3.21.15MREO @ seekingalphaEYEN @ thelincolnianonlineCitius Pharmaceuticals Announces Closing of 3 MillionRegistered Direct Offering - The Eastern Progress OnlineMCRB @ gurufocusLXRX @ financeINZY @ thelincolnianonlineMREO @ financeTERN @ gurufocusABOS @ MacroaxisInsider4.37HOOK @ gurufocusHOOK @ globenewswireABOS @ thelincolnianonlineInozyme shares remain Outperform at Raymond James,target reduced amid study focus - Investing.comARDX @ newsIBRX @ financeBLRX @ seekingalphaMCRB @ newsXFOR @ financeEYEN @ newsLXRX @ newsIBRX @ newsXFOR @ newsHOOK @ financeMREO @ MacroaxisInsiderABOS @ newsDAWN @ newsFBIO @ financeEYEN @ gurufocusXFOR @ gurufocusMCRB @ MacroaxisInsiderMREO @ newsTERN @ MacroaxisInsiderFBIO @ thelincolnianonlineIBRX @ businesswireDAWN @ kalkinemediaBLRX @ financeHOOK @ newsARDX @ seekingalphaMCRB @ thelincolnianonlineDAWN @ zacksEYEN @ financeARDX @ MacroaxisInsiderFBIO @ gamespotTERN @ globenewswireARDX @ simplywallDAWN @ thelincolnianonlineFebMar
JavaScript chart by amCharts 3.21.15JanFeb

Citius Pharmaceuticals Related Hype Analysis

Having access to credible news sources related to Citius Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Citius Pharmaceuticals' future price movements. Getting to know how Citius Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Citius Pharmaceuticals may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
XFORX4 Pharmaceuticals(0.05)9 per month 7.25  0.06  26.42 (13.51) 68.45 
HOOKHookipa Pharma 0.30 10 per month 0.00 (0.1) 6.90 (7.39) 32.80 
MREOMereo BioPharma Group 0.20 7 per month 0.00 (0.14) 6.16 (6.32) 20.77 
GRTXGalera Therapeutics 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
ABOSAcumen Pharmaceuticals(0.22)5 per month 0.00 (0.22) 6.57 (6.19) 15.46 
FBIOFortress Biotech 0.05 11 per month 3.03  0.02  9.76 (5.50) 24.02 
EYENEyenovia 0.09 8 per month 0.00 (0.16) 20.16 (17.81) 65.21 
OCUPOCUP Old 0.00 0 per month 0.00  0.00  0.00  0.00  0.00 
INZYInozyme Pharma(0.32)5 per month 0.00 (0.17) 7.72 (8.61) 38.13 
TERNTerns Pharmaceuticals(0.01)9 per month 0.00 (0.13) 5.17 (6.75) 26.61 
DAWNDay One Biopharmaceuticals 0.04 10 per month 0.00 (0.17) 3.82 (3.81) 22.86 
BLRXBioLineRx(0.86)4 per month 0.00 (0.20) 9.73 (15.04) 60.21 
ARDXArdelyx(0.67)9 per month 4.35  0.04  8.32 (7.87) 27.51 
LXRXLexicon Pharmaceuticals 0.09 7 per month 5.17  0.01  14.49 (8.43) 32.67 
MCRBSeres Therapeutics(0.03)7 per month 3.12  0.04  8.14 (5.38) 28.50 
IBRXImmunitybio 0.01 8 per month 0.00 (0.05) 9.81 (7.46) 40.65 

Citius Pharmaceuticals Additional Predictive Modules

Most predictive techniques to examine Citius price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Citius using various technical indicators. When you analyze Citius charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Citius Pharmaceuticals Predictive Indicators

The successful prediction of Citius Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Citius Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Citius Pharmaceuticals based on analysis of Citius Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Citius Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Citius Pharmaceuticals's related companies.

Story Coverage note for Citius Pharmaceuticals

The number of cover stories for Citius Pharmaceuticals depends on current market conditions and Citius Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Citius Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Citius Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Citius Pharmaceuticals Short Properties

Citius Pharmaceuticals' future price predictability will typically decrease when Citius Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Citius Pharmaceuticals often depends not only on the future outlook of the potential Citius Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Citius Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding173.9 M
Cash And Short Term Investments3.3 M

Additional Tools for Citius Stock Analysis

When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Trending Assets

GRTX
Galera Therapeutics
0.00  0.00  0.00 
ARDX
Ardelyx
5.36  0.14  2.68 
DAWN
Day One Biopharmaceu
9.06  -0.38  -4.03 
BLRX
BioLineRx
3.35  0.03  0.90 
PricesInvestor S…